FDA Nod for Fifth Stelara Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Dong-A ST’s Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar referencing Stelara. Imuldosa is a biosimilar to Stelara which is approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Ustekinumab blocks interleukin (IL)-12 and -23. Dong-A Socio Holdings and Meiji Seika Pharma began joint development […]